On or around 05/13/2019 (Notice of voluntarily dismissal)
Filing Date: April 15, 2019
According to the Complaint, AmpliPhi BioSciences is a clinical-stage biotechnology company that works to develop bacteriophage-based therapies for the treatment of antibiotic-resistant bacterial infections. The Company is engaged in identifying and developing naturally occurring bacteriophages in order to develop second-generation bacteriophage products. The Company develops these phage products with the intention of targeting a specific disease-causing bacterial-pathogen.
On January 4, 2019, the Company issued a press release announcing the proposed merger of the Company with C3J Therapeutics, Inc.
The Complaint alleges that on April 04, 2019, in order to convince the Company’s stockholders to vote in favor of the Proposed Transaction, the Board authorized the filing of a materially incomplete and misleading proxy statement with the SEC (the “Proxy Statement”), in violation of Sections 14(a) and 20(a) of the Exchange Act.
This case was voluntarily dismissed on May 13, 2019.
Company & Securities Information
Defendant: Ampliphi Biosciences Corp.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: APHB
Company Market: New York SE
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Erik Midgarden, et al. v. Ampliphi Biosciences Corp., et al.
COURT: S.D. California
DOCKET #: 19-CV-00684
JUDGE: Hon. William Q. Hayes
DATE FILED: 04/15/2019
CLASS PERIOD START: 01/04/2019
CLASS PERIOD END: 04/15/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Lifshitz & Miller 821 Franklin Avenue, Suite 209 , Lifshitz & Miller, NY 11530 (516) 493-9780 (516) 280-7376 ·
Reich Radcliffe & Hoover LLP 4675 MacArthur Court, Suite 550, Reich Radcliffe & Hoover LLP, CA 92660 949.975.0512 949.975.0514 ·
First Identified Complaint (FIC) Filings:
Complaint for Violations of the Federal Securities Laws
U.S. District Court Civil Docket
Notice of Voluntary Dismissal
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available